ListedSME

Avience Biomedicals IPO Subscription Status

Final figures at close of bidding: 15 Jul 2026, 12:00 am IST

CategorySubscription
QIB196.77x
NII597.23x
Retail (RII)401.21x
Total385.24x

Bidding day 5

Day-wise subscription

DayQIBNIIRetailTotal
Day 40.03x66.3x58.63x43.61x
Day 5196.77x597.23x401.21x385.24x

Times subscribed per category (bids vs shares offered, anchor portion excluded). Bidding has closed — these are the final figures.

How the book filled

Day-by-day demand

The Avience Biomedicals book was built over 2 days: overall subscription stood at 43.61× at the close of day 4, and finished at 385.24× on day 5. On the final day it was non-institutional investors (NII) driving the book, at 597.23× of the shares set aside for the category. More than half of the final demand arrived after day 4 — a late-building book.

Category detail

Qualified institutional buyers took their portion to 196.77×. Non-institutional investors came in at 597.23×. Retail investors put in bids for 401.21× the shares reserved for them. That puts non-institutional investors (NII) at the top of the book at 597.23× and qualified institutional buyers (QIB) at the bottom at 196.77×.

What the multiple means for allotment

With retail subscription at 401.21×, applications in that category exceeded the shares available to it by a factor of about 401.21. When a retail book is oversubscribed, the registrar does not allot proportionately — allotment runs as a computerised lottery among all valid applications, with each successful application receiving at least one lot of 600 shares — ₹1,24,800 of stock at the upper band. The multiple above is the data point that determines how thinly that draw is spread; it describes the final book, not the outcome of any single application.

Frequently asked questions

When does the Avience Biomedicals IPO open and close?
The Avience Biomedicals IPO opens on 18 Jun 2026 and closes on 22 Jun 2026.
How many times was the Avience Biomedicals IPO subscribed?
The Avience Biomedicals IPO was subscribed 385.24 times in total across all investor categories.
What is the reservation split in the Avience Biomedicals IPO?
Of the total shares offered, retail investors get 35.08%, QIBs 19.95% (plus 29.88% anchor), non-institutional investors 15.09%.